Scientist II, Cancer Genomics, Clinical Biomarker Development

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, including daraxonrasib (RMC-6236), elironrasib (RMC-6291), zoldonrasib (RMC-9805), and RMC-5127, currently in clinical development.

About the role

In this role, you will join the Cancer Genomics group in Clinical Biomarker Development, part of the Translational Medicine department, to develop biomarker, technology, and computational strategies for our RAS(ON) inhibitor programs. You will drive the application of advanced genomics analyses to maximize insight generation from clinical samples in our Phase I-III studies. This role offers the chance to work in a collaborative and innovative environment, including on cross-functional teams with computational scientists, biomarker leads, biostatisticians, and preclinical scientists.

Responsibilities

• Apply advanced analytics and genomics solutions to clinical biomarker data to inform research & development.
• Integrate multi-omics datasets to interrogate disease biology and prognosis, mechanisms of resistance, and predict drug response.
• Collaborate with cross-functional teams, managing interactions with key stakeholders to deliver robust biomarker analyses and recommend follow-up actions.
• Communicate results to expert and non-expert audiences, including internal cross-functional team members and external collaborators, through scientific publications and presentations.

Requirements

• Ph.D. in Cancer Genomics, Genetics, Computational Biology, Bioinformatics, or a similar degree.
• Minimum of 2–6 years post-PhD experience analyzing cancer genomics data (post-doc, biotech, pharma, diagnostics, or combination).
• Strong foundation in cancer biology, preferably with an understanding of RAS/MAPK signaling pathways in pancreatic, lung, or colorectal cancer.
• Proficiency programming in R and/or Python, and expertise in clearly documenting work with a version control system (git).
• Experience in Linux and the cloud, including HPC clusters and command-line interface, and developing genomics workflows for large-scale NGS datasets.
• Experience analyzing ctDNA or other liquid biopsy data derived from blood samples.
• Experience in the interrogation of DNA sequence data derived from tumor tissue, such as gene-panel, whole-exome, or whole-genome data and downstream analytics (clonality estimates, copy number variation, chromosomal instability, mutational signatures, etc).
• Practiced in commonly used tools and methods for DNA data analysis (GATK, Bioconductor, etc) and in utilizing publicly available datasets (TCGA, cBioPortal) to interrogate cancer genomics data.
• Strong understanding of statistics and the ability to generate robust predictive models with multidimensional data.
• Strong interpersonal, verbal, and written communication skills; proactive, self-motivated, and adaptable in a dynamic environment.
• Demonstrated ability to translate complex data into clear biological insight and to influence project direction through data-driven scientific inquiry.

Preferred Skills

• Experience analyzing clinical endpoints (ORR, PFS, OS) including survival analysis.
• Longitudinal ctDNA data analysis for predicting clinical endpoints (ORR, PFS, OS).
• Deep knowledge of pancreatic, lung, or colorectal cancer, preferably including how progression, response, and resistance may be mediated by biomarkers detected in tissue and/or blood.

Pay

Base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA: $132,000 – $166,000 USD. The range will be adjusted for the local market where a candidate is based. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.

Benefits

Competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.